170P: Survival of lung adenocarcinoma patients with uncommon EGFR mutations in routine clinical practice in Slovenia

Abstract

S131study started in January 2012 and included pts who started treatment with gefitinib prior to study entry or at study entry (referred to as 'new pts'). Efficacy, safety and quality of life with gefitinib were assessed over a two-year follow up period. Results: A total of 361 pts were recruited across 104 sites up to March 2013, including 116 (32%) 'new' pts. Pt characteristics are presented in the table. Objective response rate (ORR), based on clinician assessment, was 66.8% (95% confidence interval [CI] 60.3; 70.3) in the overall population and 68.8% (95% CI 59.1; 76.7) in 'new' pts. Median duration of follow up was 20.6 months. Median progression-free survival (PFS) was 11.1 months (95% [CI 10.0, 11.9) in the overall population and 10.0 months (95% CI 7.7, 11.8) for 'new' pts. Median overall survival (OS) from initiation of gefitinib was 24.6 months (95% CI 21.4, 26.7) and 24.0 months (95% CI 20.5, 27.5) in the overall population and 'new' pts, respectively. Most frequently reported treatment-related adverse events were skin (24.6%) and GI (19.6%) disorders.